MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Nasdaq Stock Market has halted trading of the company’s stock.
The U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel is meeting today to review the premarket approval application (PMA) for Cologuard, Exact’s stool DNA-based, non-invasive colorectal cancer screening test.
Help employers find you! Check out all the jobs and post your resume.
